Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 May 2007, Vol. 109, No. 9, pp. 3617-3618.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinberg, K. I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Weinberg, K. I.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

InsideBlood

TRANSPLANTATION

Comment on Hauri-Hohl et al, page 4080

ProTECtion from posttransplantation immune deficiency?

Kenneth I. Weinberg

STANFORD UNIVERSITY

Graft-versus-host disease is associated with poor thymic function and immune reconstitution after hematopoietic stem cell transplantation. Hauri-Hohl and colleagues have elucidated the mechanism by which GVHD damages the thymus.

In this issue of Blood, Hauri-Hohl and colleagues resolve a key issue in understanding how graft-versus-host disease (GVHD) leads to prolonged immune deficiency after hematopoietic stem cell transplantation (HSCT). Clinical studies have established that the occurrence of acute GVHD is a major predictor of the likelihood of opportunistic infection in hematopoietic stem cell (HSC) transplant recipients.1 Of interest, recipients of an unrelated donor (URD) HSC transplant, including those who do not develop clinical GVHD of the skin, gut, or liver, have a rate of infection that is comparable with those of matched related donor (MRD) recipients with GVHD. While there is no doubt a role for the effects of intensive immunosuppressive medications in the increased clinical infection rate, GVHD itself has profound effects on immune reconstitution after transplantation. For example, critical for the development of a broad and durable immunologic repertoire after HSCT is the generation of new T lymphocytes in the thymus from donor-derived progenitors.2 The occurrence of GVHD is associated with the decreased production of new T lymphocytes.2,3

Hauri-Hohl and colleagues have advanced the field significantly by establishing the immunologic mechanisms by which alloreactive T cells recognize and attack the thymus (see figure). Thirty years ago, Seemayer et al first proposed that the thymus may be a target of GVHD after demonstrating infiltration of the thymus by donor T lymphocytes in experimental murine models.4 Key to the present studies were analyses of both in vivo and in vitro murine models of thymopoiesis and allogeneic transplant that demonstrate that even unprimed T cells can recognize allogeneic antigens presented by thymic epithelial cells (TECs). After allogeneic recognition of the TECs, the donor T cells secrete interferon-gamma (IFN-{gamma}), which activates a STAT-1–induced apoptotic pathway in the TECs. The authors propose that the unique biology of TECs as intrathymic presenters of self-antigen to developing thymocytes allows them to present antigen and prime allogeneic immune responses, even in the absence of typical hematopoietically derived professional antigen-presenting cells (APCs). Although APC depletion has been proposed as a strategy to decrease acute GVHD, the authors' results indicate that this would not prevent the development of thymic injury.


Figure 1
View larger version (71K):
[in this window]
[in a new window]

 
Illustration of how killing of thymic epithelial cells (TECs) by alloreactive T lymphocytes can lead to posttransplantation immune deficiency. Alloreactive primed or unprimed naive T lymphocytes enter the recipient thymus after HSCT. As a result of T-cell receptor–mediated recognition of alloantigens presented by the TECs, the alloreactive T cells secrete interferon-gamma (IFN-{gamma}). The TEC response to interferon signaling includes activation of the STAT1 transcription factor, leading to an apoptotic program and TEC death. The loss of TECs results in defective microenvironmental support of thymopoiesis via numerous molecules such as the Notch ligand Dll1, the cytokines IL-7 and Kit ligand (KL), and the chemokines TECK and CXCL12. The resultant decrease in T-cell production ultimately leads to immune deficiency.

 
The destruction of TECs by alloreactive T lymphocytes may have implications for allogeneic HSCT beyond leading to immune deficiency from prolonged defects in T lymphopoiesis. A recently recognized function of the medullary TEC subset in the development of central tolerance is the negative selection of thymocytes that might develop into autoreactive T lymphocytes. A primary disease of immune development and regulation, the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, is due to loss-of-function mutations of the autoimmune regulator (Aire) gene that controls expression and presentation of self-antigens by medullary TECs.5 While it has been generally assumed that donor-derived T cells that develop in the host thymus after HSCT are host tolerant, the destruction of medullary TECs could lead to defects in central tolerance and consequent autoimmunity. Thus, the destruction of TECs as a result of acute GVHD may provide an etiologic link between the alloreactivity of acute GVHD and the autoimmunity typically seen in chronic GVHD.

GVHD has traditionally been assessed and graded in the skin, gut, and liver. As shown by Hauri-Hohl et al, the ability of TECs to present antigen is a mechanism by which GVHD in the thymus could occur without any overt clinical acute GVHD of the typical sites. The occurrence of thymic GVHD without concomitant skin, gut, or liver disease could be a confounder of clinical studies aimed at preventing either GVHD or posttransplantation immune deficiency. For example, is the increased risk of infection and poorer immune reconstitution in URD HSC transplant recipients without overt GVHD due to undiagnosed thymic GVHD?1 In contrast to the tools available for the diagnosis of skin, gut, or liver acute GVHD (physical examination, biomarkers of inflammation, biopsy, endoscopy), routine diagnosis of acute GVHD of the thymus is not readily available. The development of minimally invasive tools for diagnosis of thymic GVHD (eg, imaging or biomarker based) may be a methodologic necessity to assess thymic GVHD. Interventions to improve immune reconstitution via specific protection of TECs may be both necessary and feasible. One candidate strategy would use keratinocyte growth factor (KGF), which has been shown to protect TECs from chemotherapeutic, radiotherapeutic, and allogeneic injury after HSCT, and to stimulate TEC regeneration in aging mice.68 The elegant mechanistic studies by Hauri-Hohl et al should stimulate the identification of other potential targets, such as T-cell entry into the thymus or interferon-induced Stat-1 activation in TECs.

Footnotes

Conflict-of-interest disclosure: The author declares no competing financial interests. {blacksquare}

REFERENCES

  1. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantation: comparison of related and unrelated donor transplant recipients. Blood 1995; 86:3979–3986.[Abstract/Free Full Text]

  2. Douek DC, Vescio RA, Betts MR, et al. Assessment of thymic output in adults after haematopoietic stem-cell transplant and prediction of T-cell reconstitution. Lancet 2000; 355:1875–1881.[CrossRef][Medline] [Order article via Infotrieve]

  3. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 2001; 97:1458–1466.[Abstract/Free Full Text]

  4. Seemayer TA, Lapp WS, Bolande RP. Thymic involution in murine graft-versus-host reaction: epithelial injury mimicking human thymic dysplasia. Am J Pathol 1977; 88:119–133.[Abstract]

  5. Anderson MS, Venanzi ES, Chen Z, et al. The cellular mechanism of Aire control of T-cell tolerance. Immunity 2005; 23:227–239.[CrossRef][Medline] [Order article via Infotrieve]

  6. Min D, Taylor PA, Panoskaltsis-Mortari A, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 2002; 99:4592–4600.[Abstract/Free Full Text]

  7. Rossi S, Blazar BR, Farrell CL, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood 2002; 100:682–691.[Abstract/Free Full Text]

  8. Min D, Panoskatsis-Mortari A, Kuro-o M, Hollander GA, Blazar BR, Weinberg KI. Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. 2007; 109:2529–2537.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation
Mathias M. Hauri-Hohl, Marcel P. Keller, Jason Gill, Katrin Hafen, Esther Pachlatko, Thomas Boulay, Annick Peter, Georg A. Holländer, and Werner Krenger
Blood 2007 109: 4080-4088. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinberg, K. I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Weinberg, K. I.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020